Brainstorm Cell Therapeutics (BCLI) Stock Rises Today Ahead of ALS Treatment …
December 31, 2014 - als
NEW YORK (TheStreet) — Shares of Brainstorm Cell Therapeutics
(BCLI) soared 20.88% to $4.69 on higher-than-average volume in morning trade Wednesday brazen of a biotech company’s information recover on Monday.
Brainstorm intends to recover a final formula from a Phase 2a hearing of a branch dungeon therapy NurOwn on Monday. The association describes NurOwn as an “autologous, adult branch dungeon therapy technology” designed to yield ALS, also famous as Lou Gehrig’s Disease.
The association will horde a discussion call on Monday to plead a results.
Exclusive Report: Jim Cramer’s Best Stocks for 2015
“We are really vehement to share a final formula of this study,” pronounced Brainstorm’s CEO Tony Fiorino, MD, PhD, in a association statement. “Professor Karussis presented a really certain and well-received halt research of this investigate during a Joint Congress of European Neurology in Jun 2014, and a final formula embody information from several additional subjects and analyses conducted by a eccentric statisticians.”
“The halt research of this study, and formula of a before proviso 1/2 study, have shown that a singular sip of NurOwn™ is protected and can yield clinically suggestive advantages to ALS patients, such as a rebate in a rate of progression, and in some patients, tangible improvements in function,” Fiorino continued. “The final formula will extend these commentary and concede us to pierce brazen with a display and announcement plan so that we might share these critical information with a medical and systematic colleagues.”